Board

Geoffrey N. Vernon - Non-Executive Chairman

Dr. Vernon Chairman of XL Tech Group Plc and is a former executive director of Rothschild Asset Management Ltd., partner of the venture capital group Advent Limited, and has over 20 years' experience in healthcare and life sciences. Dr. Vernon is chairman and/or non-executive director of a number of quoted and privately owned companies in the UK, Germany, Ireland and Israel. He is also a Fellow of the Institute of Directors and one of the first directors in the UK to be admitted as a Chartered Director.

Member of the Audit Committee and chairman of the Nomination Committee.

Alan Reade - Independent Non-executive Director

Mr Reade is owner of Global Strategy Expression Company, a consulting and advisory services business in the life sciences industry. From 2000 until his retirement in 2005, he served as executive chairman of Merial Limited, a leading animal health company and joint venture between Merck & Co. Inc. and Sanofi-Aventis. Earlier in his career, Mr Reade was head of global integration at Aventis, where he was in charge of merger integration, and Chief Executive Officer and member of the Global Executive Committee at Rhone-Poulenc Inc. He previously has been a director of Sygen International and IFAH, a global animal health association as well as more than 40 Merial subsidiaries.

Chairman of the Remuneration Committee and member of the Nominations Committee

Barrington Marshall Riley - Independent Non-executive Director

After qualifying as a Chartered Accountant, Barry Riley joined the Bowater Organisation, where he had responsibility for the finance function at several operations. From there he moved to FMC Corporation, the US conglomerate where he had general management responsibilities for a specialty chemical operation, and also oversaw the head office finance function for all UK operations. He joined Proteus International plc in 1995 as Finance Director and was closely involved in the merger with Therapeutic Antibodies Inc. in 1999. He is currently Finance Director of Protherics Plc.

Chairman of the Audit Committee and member of the Nominations Committee

Ken Noonan - Independent Non-executive Director.

Dr. Noonan is Partner at LEK Consulting LLP based in London, where he leads the firm's life sciences practice in the UK and Europe, with responsibility for pharmaceuticals, biotechnology and in vitro diagnostics. He is currently a technology partner at Advanced Technology Partners. Other positions held by Dr. Noonan included Senior Vice President of Corporate Development for Applera Corporation and Vice President at Booz-Allen & Hamilton and head of its European Pharmaceutical Practice. He currently serves on the Board of Orchid Biosciences Inc and Intercept Pharmaceuticals Inc. During his academic career Dr. Noonan authored over 50 articles in the cancer biology/cell replication and holds a B.S. from St Josephs University and a Ph.D. in Biochemistry from Princeton University.

Member of the Audit Committee and of the Remuneration Committee and Senior Independent Non Executive Director.

David Paul Szostak - Non-executive Director.

Mr. Szostak is an Executive Director, Chief Financial Officer and Company Secretary at XL TechGroup, Inc. (AIM: XLT), and began his career in Chicago, Illinois working as a certified public accountant (CPA) for a large size accountancy firm (Laventhol and Howarth) and later other smaller accounting firms. He then moved into industry in 1987 as corporate controller at Extel, Inc., a global manufacturer of electronic communication equipment for industry and governments. When Extel acquired Hetra Computer, Inc., a manufacturer of government specialty computers, in 1990, Mr. Szostak relocated to Florida and accepted the position of vice president and CFO of Hetra. In 1993, when XL Vision, the predecessor company to XL TechGroup, acquired Hetra, Mr. Szostak continued in the same position with XL Vision. During his tenure at XL Vision, he was active in both the fundraising and public offerings of the XL Vision spin-out businesses. In addition to the accounting and finance functions, Mr. Szostak was responsible for many of the internal functions such as human resources and benefits, legal, travel and facilities. Mr. Szostak earned his Bachelor of Science in Finance at Southern Illinois University, with graduate studies at DePaul University in Chicago.

Dr. R. Douglas Armstrong - Chief Executive Officer

Dr. Armstrong has over twenty years' experience in the assessment and development of biotechnologies, as well as in-depth corporate management experience at public and private biotechnology, medical device and developmental research companies. Prior to his appointment at TyraTech, Dr. Armstrong was CEO and Chairman of Aastrom Biosciences Inc., which he led from start-up, through development, and a public offering on NASDAQ. He has also served on the boards of VisualSonics Inc., Nephros Therapeutics Inc., Cytomedix Inc., Zellera AG (Germany), and the Burnham Institute, where he also served as the Executive Vice President. In addition, Dr. Armstrong has served as a member of the advisory board of Wolverine Venture Fund, and an advisor to Auxol Capital. Dr. Armstrong is a graduate in Chemistry from the University of Richmond, Virginia and he also holds a PhD in Pharmacology & Toxicology from the Medical College of Virginia, at Virginia Commonwealth University.

Keith Bigsby - Chief Financial Officer

After qualifying as a Chartered Accountant, Mr. Bigsby has had over 30 years of senior financial management and board room experience in the technology sector. Mr. Bigsby has held senior finance positions across Europe, the USA and the Far East, a significant proportion of which has been as Chief Financial Officer (including for publicly listed companies) most recently at Geotrupes Energy Plc and Tadpole Technology Plc. Prior to this he was for six years the European Regional CFO for Wang and held Regional Finance Director roles in the UK and France for Sun Microsystems. He has a significant background in complex business environments, strategic planning and process re-engineering.